GlassScriptPhysician profile
Ajay Sehgal
NPI 1164529806
$17,192.77
in general payments reported to CMS, 2019-2025
64 companies · $4,190 in 2025
The $4,190 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $580 · 2021: $1,872 · 2022: $2,487 · 2023: $2,735 · 2024: $4,285 · 2025: $4,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,870 · Long Term Medical Supply Or Device Loan: $2,164 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,870.27 |
| Long Term Medical Supply Or Device Loan | $2,163.62 |
| Education | $176.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,537.85 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,817.71 | 2019-2025 | Opdivo, Opdualag, Breyanzi |
| Merck Sharp & Dohme LLC | $1,015.91 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $986.84 | 2020-2025 | Enhertu, Imfinzi, Tagrisso |
| Pfizer INC. | $785.31 | 2019-2025 | |
| Janssen Biotech, INC. | $756.72 | 2019-2025 | Erleada, Rybrevant, Akeega |
| Celgene Corporation | $549.15 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Karyopharm Therapeutics INC. | $423.10 | 2020-2025 | Xpovio |
| Astellas Pharma US INC | $366.58 | 2021-2025 | Vyloy, Xtandi, Padcev |
| Eisai INC. | $348.87 | 2021-2025 | |
| Lilly USA, LLC | $344.53 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $335.97 | 2020-2025 | Monjuvi, Jakafi |
| Gilead Sciences, INC. | $327.73 | 2021-2025 | Trodelvy |
| Genentech USA, INC. | $325.37 | 2019-2025 | Tecentriq, Polivy, Lunsumio |
| Takeda Pharmaceuticals U.S.A., INC. | $316.08 | 2021-2025 | Fruzaqla, Iclusig, Alunbrig |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $286.65 | 2020-2025 | Enhertu |
| Glaxosmithkline, LLC. | $277.34 | 2021-2025 | Ojjaara, Zejula, Shingrix |
| Genzyme Corporation | $244.51 | 2020-2025 | |
| Taiho Oncology, INC. | $242.86 | 2022-2025 | |
| Kite Pharma, INC. | $231.18 | 2019-2023 | Yescarta |
| Abbvie INC. | $219.04 | 2019-2025 | |
| Adc Therapeutics America, INC. | $209.70 | 2021-2024 | |
| Seagen INC. | $203.84 | 2020-2023 | Tukysa, Adcetris |
| Puma Biotechnology, INC. | $191.71 | 2020-2025 | Nerlynx |
| Regeneron Healthcare Solutions, INC. | $188.61 | 2021-2025 | Libtayo |
| Exelixis INC. | $182.37 | 2020-2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $179.62 | 2022-2023 | Fotivda |
| Array Biopharma INC | $177.79 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Ipsen Biopharmaceuticals, INC | $175.95 | 2023-2025 | Onivyde, Somatuline Depot |
| Stryker Corporation | $169.87 | 2024 | Spy-Phi System |
| Beigene USA, INC. | $137.83 | 2020-2024 | Brukinsa |
| Melinta Therapeutics, LLC | $129.93 | 2022 | |
| Genmab U.S., INC. | $123.55 | 2025 | Epkinly |
| Mirati Therapeutics, INC. | $119.15 | 2023-2024 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $114.33 | 2022-2025 | |
| Sobi, INC | $104.99 | 2022-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $95.77 | 2021-2023 | Imbruvica |
| Nevro Corp. | $82.71 | 2022 | |
| Morphosys, US INC. | $80.96 | 2021-2023 | Monjuvi |
| Pharmaessentia USA Corporation | $52.69 | 2025 | Besremi |
| Emd Serono, INC. | $48.46 | 2019-2023 | Bavencio |
| Stemline Therapeutics INC. | $48.25 | 2023-2025 | Orserdu |
| Dova Pharmaceuticals | $43.60 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.97 | 2021 | |
| Clovis Oncology, INC. | $39.88 | 2019 | |
| Coherus Oncology, INC. | $38.26 | 2023 | |
| Myovant Sciences INC. | $37.84 | 2021 | |
| Rigel Pharmaceuticals, INC. | $37.59 | 2021-2025 | Tavalisse, Gavreto, Rezlidhia |
| Tolmar, INC. | $33.19 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $33.19 | 2025 | Rubraca |
| Alexion Pharmaceuticals, INC. | $30.00 | 2024 | Ultomiris |
| Sandoz INC. | $29.03 | 2020-2021 | |
| Secura Bio, INC. | $29.02 | 2022 | |
| Epizyme, INC. | $28.40 | 2021-2022 | |
| Organon LLC | $28.26 | 2024 | |
| Mylan Institutional INC. | $27.63 | 2021-2023 | Ogivri, Fulphila |
| Geron Corporation | $25.92 | 2025 | Rytelo |
| Beone Medicines USA, INC. | $24.92 | 2025 | Brukinsa |
| Janssen Pharmaceuticals, INC | $22.00 | 2024 | Rybrevant |
| Tempus Ai, INC | $20.21 | 2024 | |
| Immunogen, INC. | $19.63 | 2023 | Elahere |
| Blueprint Medicines Corporation | $17.59 | 2021 | |
| Springworks Therapeutics, INC. | $14.81 | 2024 | Ogsiveo |
| Jazz Pharmaceuticals INC. | $14.45 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Sehgal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.